Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Boston Scientific (NY: BSX )

91.50 +1.33 (+1.47%)
Official Closing Price Updated: 4:10 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Boston Scientific

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Key Takeaways From Boston Scientific Analyst Ratings
Via Benzinga
Why Is Medical Device Giant Boston Scientific Stock Trading Higher On Monday?
Boston Scientific's latest trial shows safety and efficacy endpoints for stroke prevention in atrial fibrillation patients. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
NYSE:BSX may be ready to breakout.
Technical Setup: BOSTON SCIENTIFIC CORP Appears Poised for a Breakout. 
Via Chartmill
Don’t Confuse Brains With A Bull Market, Or Price With Value
If you are interested in the stock market, maybe it is time to stop focusing on The Fed. 
Via Talk Markets
Why is Boston Scientific Stock Trading Lower On Wednesday?
Boston Scientific's ACURATE IDE trial results showed a 16.16% composite rate for mortality, stroke, or rehospitalization, not meeting non-inferiority versus controls. 
Via Benzinga
$1000 Invested In This Stock 15 Years Ago Would Be Worth $11,000 Today
Via Benzinga
Behind the Scenes of Boston Scientific's Latest Options Trends
Via Benzinga
Boston Scientific Earnings, Sales Top Q3 Views; Stock Eyes High
The medtech giant beat on the top and bottom line early Wednesday. 
Via Investor's Business Daily
Stock Market Mixed But Nasdaq Hits Record High As Tesla Leads Earnings Winners: Weekly Review
The major indexes were mixed for the week. 
Via Investor's Business Daily
Boston Scientific Pauses Enrollment In Farapulse Study In Drug-Naive Patients With Irregular Heart Rhythm
Boston Scientific's AVANT GUARD trial evaluates the FARAPULSE PFA System for treating persistent atrial fibrillation, pausing enrollment to assess trial observations. 
Via Benzinga
Boston Scientific Q3 Earnings: Revenue And EPS Beat, Lifts Annual Forecast On Strong Demand For Heart Devices
Boston Scientific exceeded Q3 expectations with $4.21 billion revenue and $0.63 EPS. Cardiovascular sales rose 25%, and 2024 growth guidance was updated. 
Via Benzinga
Boston Scientific's Options Frenzy: What You Need to Know
Via Benzinga
Key Takeaways From Boston Scientific Analyst Ratings
Via Benzinga
Performance Comparison: Boston Scientific And Competitors In Health Care Equipment &amp; Supplies Industry
Via Benzinga
Is BOSTON SCIENTIFIC CORP Ready to Break Out of Its Range?
BOSTON SCIENTIFIC CORP (NYSE:BSX) has a good technical rating of 10 out of 10 and could possibly break out. 
Via Chartmill
Wall Street Slumps For Third Straight Day As Investor Sentiment Fades, Dollar Strength Resumes, Boeing Disappoints: What's Driving Markets Wednesday?
Wall Street is on track for its third consecutive day of losses as investors grow cautious about risky assets, awaiting more clarity on U.S. fiscal and monetary policies and scrutinizing the latest... 
Via Benzinga
Critical Insights From Boston Scientific Analyst Ratings: What You Need To Know
Via Benzinga
US Hospitals Face Critical IV Fluid Shortage After Baxter Facility Shuts Down Due To Hurricane Helene
The U.S. faces a critical shortage of IV fluids due to Hurricane Helene's damage to Baxter's North Carolina plant, forcing hospitals to delay surgeries. Federal efforts to rebuild and import supplies... 
Via Benzinga
If You Invested $1000 In This Stock 15 Years Ago, You Would Have $8,100 Today
Via Benzinga
Spotlight on Boston Scientific: Analyzing the Surge in Options Activity
Via Benzinga
This Boston Scientific Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Via Benzinga
Solventum Stock Earns 81 RS Rating
Solventum stock saw a positive improvement to its Relative Strength Rating on Tuesday, with an upgrade from 78 to 81. 
Via Investor's Business Daily
Here's How Much You Would Have Made Owning Boston Scientific Stock In The Last 10 Years
Via Benzinga
18 Stocks To Buy, 7 To Sell This Earnings Season: Goldman Sachs Calls It 'The Year Of The Stock Picker'
Goldman Sachs identifies 18 stocks for potential earnings upside and advises options-based strategies in a volatile market. 10% upside for S&P 500. 
Via Benzinga
Topics Stocks
Exposures US Equities
If You Invested $1000 In This Stock 15 Years Ago, You Would Have $6,900 Today
Via Benzinga
In-Depth Examination Of 18 Analyst Recommendations For Boston Scientific
Via Benzinga
Here's How Much You Would Have Made Owning Boston Scientific Stock In The Last 10 Years
Via Benzinga
Growth At Any Price (GAAP) Is A Bad Strategy. Valuation Matters.
The current leadership in the stock market is clearly not tech, or the Magnificent 7. 
Via Talk Markets
This Is Great News for Medtronic, but Is It Time to Buy the Stock?
This MedTech leader is back on track with profitable growth. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.